Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies.

[1]  G. Mancardi,et al.  Stem cell transplantation in multiple sclerosis , 2010, Current opinion in neurology.

[2]  M. Mayes,et al.  Denials Of Treatment Coverage By Health Insurance Carriers Restrict Patient Recruitment On A Randomized Clinical Trial: Experience Of 95 Patients With Systemic Sclerosis (SSc) Enrolled In The SCOT (Scleroderma: Cyclophosphamide Or Transplantation) Trial , 2010 .

[3]  M. Labopin,et al.  Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years’ experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases , 2010, Haematologica.

[4]  T. Hügle,et al.  Allogeneic hematopoietic SCT for patients with autoimmune diseases , 2009, Bone Marrow Transplantation.

[5]  M. Stangel.  Multiple sclerosis: Hematopoietic stem cell transplantation: hope and hype , 2009, Nature Reviews Neurology.

[6]  A. Testori,et al.  Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study , 2009, The Lancet Neurology.

[7]  Luca Roccatagliata,et al.  Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta‐analytic approach , 2009, Annals of neurology.

[8]  A. Zander,et al.  Stem cell transplantation in multiple sclerosis , 2008, Journal of Neurology.

[9]  M. Labopin,et al.  Autologous Hematopoietic Stem Cell Transplantation (HSCT) for Autoimmune Diseases: 10 Years Experience from the European Group for Blood and Marrow Transplantation (EBMT) Working Party on Autoimmune Diseases , 2008 .

[10]  A. Bosi,et al.  Haematopoietic stem cell transplantation for autoimmune disorders , 2008, Current opinion in hematology.

[11]  K. Selmaj,et al.  Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. , 2008, The New England journal of medicine.

[12]  D. Bourdette,et al.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis , 2008, Current neurology and neuroscience reports.

[13]  C. Lederer,et al.  Disability as an outcome in MS clinical trials , 2008, Neurology.

[14]  Carrilin C. Trecker,et al.  Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. , 2008, Archives of neurology.

[15]  M. Filippi,et al.  Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives , 2008, Multiple sclerosis.

[16]  D. Arnold,et al.  Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions , 2008, Annals of neurology.

[17]  E. Havrdová,et al.  Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database , 2006, Multiple sclerosis.

[18]  D. Arnold,et al.  Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis , 2006, Neurology.

[19]  E. Frohman,et al.  Multiple sclerosis--the plaque and its pathogenesis. , 2006, The New England journal of medicine.

[20]  M. Filippi,et al.  Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis , 2005, Neurological Sciences.

[21]  M. Mayes,et al.  Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  G Keir,et al.  The new Global Multiple Sclerosis Severity Score (MSSS) correlates with axonal but not glial biomarkers , 2005, Multiple sclerosis.

[23]  M. Filippi,et al.  Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. , 2005, Blood.

[24]  D. Douek,et al.  Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients , 2005, The Journal of experimental medicine.

[25]  Y. Blanco,et al.  Autologous haematopoietic-stem-cell transplantation for multiple sclerosis , 2005, The Lancet Neurology.

[26]  Roland Martin,et al.  Development of biomarkers in multiple sclerosis. , 2004, Brain : a journal of neurology.

[27]  T. Waldmann,et al.  Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[28]  H. Hartung,et al.  Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial , 2002, The Lancet.

[29]  L. Kappos,et al.  Hematopoietic stem cell transplantation for multiple sclerosis , 2002, Journal of Neurology.

[30]  J. Fischer,et al.  Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. , 2001, Archives of neurology.

[31]  A Thompson,et al.  The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. , 2001, Brain : a journal of neurology.

[32]  J. Duda,et al.  Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon β-1a , 2000, Multiple sclerosis.

[33]  Stephen M. Rao,et al.  Development of a multiple sclerosis functional composite as a clinical trial outcome measure. , 1999, Brain : a journal of neurology.

[34]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. , 1999, Brain : a journal of neurology.

[35]  N. Simonian,et al.  “Summary measure” statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis , 1998, Journal of neurology, neurosurgery, and psychiatry.

[36]  L. Blumhardt,et al.  “Summary measure” statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis , 1998, Journal of neurology, neurosurgery, and psychiatry.

[37]  A. Anagnostopoulos,et al.  Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study , 1997, Bone Marrow Transplantation.

[38]  B Bass,et al.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. , 1989, Brain : a journal of neurology.

[39]  J. Kurtzke.  Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[40]  V. Yong,et al.  Continued disease activity in a patient with multiple sclerosis after allogeneic hematopoietic cell transplantation. , 2009, Archives of neurology.

[41]  H. Atkins,et al.  Immune ablation followed by autologous hematopoietic stem cell transplantation for the treatment of poor prognosis multiple sclerosis. , 2009, Methods in molecular biology.

[42]  J. Mussini,et al.  [Immunology of multiple sclerosis]. , 1982, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris.